Neovacs SA (FR:ALNEV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA, a French biotech firm focused on inflammatory and autoimmune diseases, has announced a capital reduction to offset losses by decreasing the nominal share value from 0.005 euro to 0.0005 euro. The company’s share capital now stands at 125,968.0985 euros, divided into 251,936,197 shares. Investors are cautioned about potential share dilution and capital loss due to the company’s dilutive financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.